HCV entry and neutralizing antibodies: Lessons from viral variants

Future Microbiology

Volumn 4, Issue 5, 2009, Pages 511-517

  Zeisel, Mirjam B ^a,b   Baumert, Thomas F ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD81 ANTIGEN; CLAUDIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C ANTIBODY; NEUTRALIZING ANTIBODY; OCCLUDIN; RIBAVIRIN; SCAVENGER RECEPTOR BI;

ANTIBODY RESPONSE; ANTIVIRAL RESISTANCE; ARTICLE; DRUG COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS PATHOGENESIS;

HEPATITIS C VIRUS;

EID: 67149114951     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.34     Document Type: Article

References (54)

1. Grove J, Nielsen S, Zhong J et al.: Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 82(24), 12020-12029 (2008).
2. Alter MJ, Margolis HS, Krawczynski K et al.: The natural history of community-acquired hepatitis C in the United-States. N. Engl. J. Med. 327, 1899-1905 (1992).
3. Feld JJ, Hoofnagle JH: Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967-972 (2005).
4. Pestka JM, Zeisel MB, Blaser E et al.: Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104, 6025-6030 (2007).
5. Diepolder HM, Zachoval R, Hoffmann-RM et al.: Possible mechanism involving T-lymphocyte response non-structural protein 3 in vital clearance in acute hepatitis C virus infection. Lancet 346, 1006-1007 (1995).
6. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194, 1395-1406 (2001).
7. Zeisel MB, Cosset FL, Baumert TF: Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 48, 299-307 (2008).
8. Thimme R, Neumann-Haefelin C, Boettler T, Blum HE: Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol. Chem. 389, 457-467 (2008).
9. Bowen DG, Walker CM: Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436, 946-952 (2005).
10. von Hahn T, Yoon JC, Alter H et al.: Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132, 667-678 (2007).
11. Keck ZY, Li SH, Xia J et al.: Mutations in HCV E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J. Virol. (2009).
12. Pileri P, Uematsu Y, Campagnoli S et al.: Binding of hepatitis C virus to CD81. Science 282, 938-941 (1998).
13. Scarselli E, Ansuini H, Cerino R et al.: The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017-5025 (2002).
14. Akazawa D, Date T, Morikawa K et al.: Cd81 expression is important for heterogeneous Hcv permissiveness of Huh7 cell clones. J. Virol. 81, 5036-5045 (2007).
15. Koutsoudakis G, Kaul A, Steinmann E et al.: Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80, 5308-5320 (2006).
16. Zeisel MB, Koutsoudakis G, Schnober EK et al.: Scavenger receptor BI is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46, 1722-1731 (2007).
17. Evans MJ, von Hahn T, Tscherne DM et al.: Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801-805 (2007).
18. Meertens L, Bertaux C, Cukierman L et al.: The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J. Virol. 82, 3555-3560 (2008).
19. Ploss A, Evans MJ, Gaysinskaya VA et al.: Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882-886 (2009).
20. Dreux M, Thi DVL, Fresquet J et al.: Receptor complementation and mutagenesis reveal SR-BI as arl-essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 5, e1000310 (2009).
21. Helle F, Dubuisson J: Hepatitis C virus entry into host cells. Cell. Mol. Life Sci. 65, 100-112 (2008).
22. von Hahn T, Rice CM: Hepatitis C virus entry. J. Biol. Chem. 283, 3689-3693 (2008).
23. Wakita T, Pietschmann T, Kato T et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796 (2005).
24. Baumert TF, Ito S, Wong DT, Liang TJ: Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol. 72, 3827-3836 (1998).
25. Barth H, Cerino R, Arcuri M et al.: Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J. Virol. 79, 5774-5785 (2005).
26. Wellnitz S, Klumpp B, Barth H et al.: Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J. Virol 76, 1181-1193 (2002).
27. Bartosch B, Dubuisson J, Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197, 633-642 (2003).
28. Hsu M, Zhang J, Flint M et al.: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100, 7271-7276 (2003).
29. Lindenbach BD, Evans MJ, Syder AJ et al.: Complete replication of hepatitis C virus in cell culture. Science 309, 623-626 (2005).
30. Zhong J, Gastaminza P, Cheng G et al.: Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294-9299 (2005).
31. Haberstroh A, Schnober EK, Zeisel MB et al.: Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 135(5), 1719-1728 (2008).
32. Rosa D, Campagnoli S, Moretto C et al.: A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc. Natl Acad. Sci. USA 93, 1759-1763 (1996).
33. Bartosch B, Verney G, Dreux M et al.: An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79, 8217-8229 (2005).
34. Steinmann D, Barth H, Gissler B et al.: Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J. Virol. 78, 9030-9040 (2004).
35. Owsianka A, Tarr AW, Juttla VS et al.: Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79, 11095-11104 (2005).
36. Zhang P, Wu CG, Mihalik K et al.: Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl Acad. Sci. USA 104, 8449-8454 (2007).
37. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA: CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 78, 1448-1455 (2004).
38. Owsianka AM, Timms JM, Tarr AW et al.: Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 80, 8695-8704 (2006).
39. Habersetzer F, Fournillier A, Dubuisson J et al.: Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 249, 32-41 (1998).
40. Keck ZY, Op De Beeck A, Hadlock KG et al.: Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 78, 9224-9232 (2004).
41. Schofield DJ, Bartosch B, Shimizu YK et al.: Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42, 1055-1062 (2005).
42. Op de Beeck A, Voisset C, Bartosch B et al.: Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 78, 2994-3002 (2004).
43. Voisset C, Callens N, Blanchard E, Op de Beeck A, Dubuisson J, Vu-Dac N: High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 280, 7793-7799 (2005).
44. von Hahn T, Lindenbach BD, Boullier A et al.: Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 43, 932-942 (2006).
45. Dreux M, Pietschmann T, Granier C et al.: High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281, 18285-18295 (2006).
46. Voisset C, Op de Beeck A, Horellou P et al.: High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV) infected patient antibodies by promoting HCV entry. J. Gen. Virol. 87, 2577-2581 (2006).
47. Farci P, Shimoda A, Coiana A et al.: The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339-344 (2000).
48. Dreux M, Cosset FL: The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J. Viral Hepat. 14(Suppl. 1), 68-76 (2007).
49. Zhong J, Gastaminza P, Chung J et al.: Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 80, 11082-11093 (2006).
50. Pugach P, Kuhmann SE, Taylor J et al.: The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321, 8-22 (2004).
51. Marsh R, Connor A, Gias E, Toms GL: Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture. J. Med. Virol. 79, 829-837 (2007).
52. Kwong PD, Doyle ML, Casper DJ et al.: HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
53. Gal-Tanamy M, Keck ZY, Yi M et al.: In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc. Natl Acad. Sci. USA 105, 19450-19455 (2008).
54. Moore JP: HIV vaccines. Back to primary school. Nature 376(6536), 115 (1995).